ECSP045244A - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
ECSP045244A
ECSP045244A EC2004005244A ECSP045244A ECSP045244A EC SP045244 A ECSP045244 A EC SP045244A EC 2004005244 A EC2004005244 A EC 2004005244A EC SP045244 A ECSP045244 A EC SP045244A EC SP045244 A ECSP045244 A EC SP045244A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compositions
fluoroanilino
chloro
methyl
condition
Prior art date
Application number
EC2004005244A
Other languages
English (en)
Inventor
Aness Abdulquadar Karnachi
Maha Y Khaled
Jurij Holinej
Yatindra Joshi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP045244A publication Critical patent/ECSP045244A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un método para tratar un trastorno o condición dependiente de ciclooxigenasa-2, que comprende administrar ácido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacético en una cantidad efectiva para tratar dicho trastorno o condición durante aproximadamente 24 horas, comprendiendo administrar oralmente una vez al día a un ser humano, con la necesidad de dicho tratamiento, una o más composiciones farmacéuticas de liberación inmediata comprendiendo ácido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacético, y composiciones adecuadas para usarse en tales métodos.
EC2004005244A 2002-03-07 2004-08-23 Composiciones farmaceuticas ECSP045244A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36235102P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
ECSP045244A true ECSP045244A (es) 2004-09-28

Family

ID=27789154

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005244A ECSP045244A (es) 2002-03-07 2004-08-23 Composiciones farmaceuticas

Country Status (20)

Country Link
US (4) US20050123604A1 (es)
EP (1) EP1492520A1 (es)
JP (1) JP2005519097A (es)
KR (1) KR20040089654A (es)
CN (1) CN1330300C (es)
AR (1) AR038747A1 (es)
AU (1) AU2003227039B2 (es)
BR (1) BR0308156A (es)
CA (1) CA2476744A1 (es)
CO (1) CO5650241A2 (es)
EC (1) ECSP045244A (es)
MX (1) MXPA04008665A (es)
NO (1) NO20044164L (es)
NZ (1) NZ534587A (es)
PE (1) PE20040288A1 (es)
PL (1) PL370907A1 (es)
RU (1) RU2318497C2 (es)
TW (1) TW200305443A (es)
WO (1) WO2003074041A1 (es)
ZA (1) ZA200406226B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
EA033102B1 (ru) * 2017-08-21 2019-08-30 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция с модифицированным отсроченным и длительным высвобождением, содержащая аспарагинаты
WO2023113650A1 (ru) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346525C2 (de) * 1983-12-22 1987-03-19 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische Zubereitung mit speziellen 1,2-Diacyl-glycero-3-phosphocholinen zur Behandlung von Erkrankungen im Magen-Darmbereich
KR100208979B1 (ko) * 1992-06-12 1999-07-15 야스이 쇼사꾸 기도내 투여용 제제
JPH08511009A (ja) * 1993-06-08 1996-11-19 チバ−ガイギー アクチェンゲゼルシャフト ジクロフェナックを含有する経口固体剤形の製造方法
BR9709097A (pt) * 1996-05-17 1999-08-03 Merck & Co Inc Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
DE19931708A1 (de) * 1999-07-08 2001-01-18 Bayer Ag Verfahren zur Herstellung schnell zerfallender, fester pharmazeutischer Zubereitungen
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
AR036312A1 (es) * 2001-08-31 2004-08-25 Novartis Ag Composicion farmaceutica

Also Published As

Publication number Publication date
US20050123604A1 (en) 2005-06-09
PE20040288A1 (es) 2004-06-24
ZA200406226B (en) 2005-06-23
US20070087051A1 (en) 2007-04-19
RU2004129770A (ru) 2005-05-10
PL370907A1 (en) 2005-05-30
MXPA04008665A (es) 2004-12-06
EP1492520A1 (en) 2005-01-05
US20090149543A1 (en) 2009-06-11
CN1330300C (zh) 2007-08-08
CN1638752A (zh) 2005-07-13
AR038747A1 (es) 2005-01-26
JP2005519097A (ja) 2005-06-30
TW200305443A (en) 2003-11-01
CA2476744A1 (en) 2003-09-12
AU2003227039B9 (en) 2003-09-16
KR20040089654A (ko) 2004-10-21
AU2003227039B2 (en) 2007-04-19
NO20044164L (no) 2004-09-30
CO5650241A2 (es) 2006-06-30
WO2003074041A1 (en) 2003-09-12
US20030171437A1 (en) 2003-09-11
NZ534587A (en) 2007-08-31
BR0308156A (pt) 2005-01-04
RU2318497C2 (ru) 2008-03-10
AU2003227039A1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
ATE461698T1 (de) Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
ATE202923T1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
DK0880350T3 (da) Behandling af dissemineret sklerose
PT840601E (pt) Thip para o tratamento de desordens do sono
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
MXPA04003739A (es) Dispositivo guia tipo leva e instalacion de moldeo que utiliza el mismo.
RU2004109920A (ru) Фармацевтическая композиция, включающая лумиракоксиб
BR0008443A (pt) Inibidores de aminotransferaseaminoácido-dependente de cadeia ramificada e seuuso no tratamento da retinopatia diabética
ATE414522T1 (de) Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure
JP4300370B2 (ja) 上皮改善剤
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
AR030630A1 (es) Composiciones farmaceuticas
NO996468D0 (no) Anvendelse av gaba-analoger slik som gabapentin i fremstillingen av et medikament for behandling av betennelsessykdommer
DE60030107D1 (de) Vitamin-d derivate zur behandlung des systemischen lupus erythematodes
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
ECSP045244A (es) Composiciones farmaceuticas
BR0115215A (pt) Método para o tratamento de inflamações
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
CN104825542A (zh) 一种医用生物牙齿脱敏剂敷料及其制备方法
DK1585513T3 (da) Anvendelse af docosahexaensyre som aktivt stof til behandling af lipodystrofi
RU2353358C2 (ru) Производные прегабалина для лечения приливов
BR0311613A (pt) Métodos para inibição, tratamento ou prevenção de sintomas de atrofia da pele, ou atrofia epitelial ou da mucosa nas mulheres e utilização de composto
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos